As Chief Development Officer, Dr. Gedrich is responsible for leading and coordinating PIC Therapeutics' translational biology and development activities for clinical proof of concept studies.

Rich has over 25 years of oncology research and development experience in the pharmaceutical and biotech industries. Most recently, Rich served as Head of Oncology Translational Sciences at Arvinas, where he built the company’s oncology translational science team and led translational strategy for multiple clinical and nonclinical programs. Prior to Arvinas, he helped lead preclinical and translational efforts at Celldex Therapeutics and Kolltan Pharmaceuticals, ushering assets from discovery into clinical proof of concept studies. Earlier in his career, Rich held various roles of increasing responsibility in nonclinical, translational and clinical biomarker research at Astellas and OSI Pharmaceuticals, and contributed to preclinical pharmacology efforts at GlaxoSmithKline and Bayer Healthcare. 

Rich received his BS from The University of Scranton and his PhD in Microbiology from the University of Virginia.